📊 NTLA Key Takeaways
Is Intellia Therapeutics, Inc. (NTLA) a Good Investment?
Intellia demonstrates severe financial stress with $100.5M operating losses on $15M revenue and $117.3M annual cash burn, providing only ~1.2 years of runway at current rates. Despite a strong balance sheet with $620.9M equity and no debt, the fundamental unprofitability (-639.5% net margin) indicates a pre-revenue stage business model far from viability. Continued dependence on capital raises will significantly dilute shareholders before any clear path to profitability emerges.
Revenue is growing modestly, but the company remains deeply unprofitable with exceptionally negative operating and net margins and heavy cash burn. Liquidity is strong and there is no debt, yet cash on hand appears insufficient relative to annual operating outflows, pointing to likely near-term financing needs. On fundamentals alone, dilution risk and unclear path to profitability outweigh current revenue traction.
Why Buy Intellia Therapeutics, Inc. Stock? NTLA Key Strengths
- Debt-free balance sheet with $620.9M stockholders' equity eliminates solvency risk
- Excellent liquidity position with 6.10x current ratio enabling sustained R&D spending
- Positive revenue growth trajectory at 16.9% YoY indicating emerging market acceptance
- Minimal interest burden and financial obligations reducing near-term distress probability
- Insider activity (7 Form 4 filings) demonstrates management stake in company direction
- Strong liquidity with 5.08x current ratio
- No long-term debt and sizable equity base
- Double-digit YoY revenue growth
NTLA Stock Risks: Intellia Therapeutics, Inc. Investment Risks
- Unsustainable cash burn of $117.3M annually against $134.7M cash reserves yields ~1.2 year runway
- Operating losses of $100.5M represent -668% margin on $15M revenue, demonstrating non-viable unit economics
- Revenue base is immaterial relative to operating expenses; requires >10x revenue growth to approach breakeven
- Mandatory equity capital raises for survival will create substantial shareholder dilution
- Early-stage biotech with no visibility into clinical trial success, regulatory approval timeline, or commercialization feasibility
- Sustained large operating losses and >600% negative margins
- Severe negative operating cash flow and FCF implying short runway
- Small, potentially volatile collaboration-driven revenue base
Key Metrics to Watch
- Quarterly operating cash burn rate trend and months of runway remaining
- Revenue growth rate, customer concentration, and path to $100M+ annual revenue
- Operating loss reduction trajectory and progress toward gross margin inflection
- Capital raise announcements and resulting shareholder dilution impact
- Clinical pipeline milestones and trial advancement rates affecting long-term viability
- Operating cash flow (burn rate)
- Cash & equivalents / months of runway
Intellia Therapeutics, Inc. (NTLA) Financial Metrics & Key Ratios
💡 AI Analyst Insight
Strong liquidity with a 6.10x current ratio provides a solid financial cushion.
NTLA Profit Margin, ROE & Profitability Analysis
NTLA vs Healthcare Sector: How Intellia Therapeutics, Inc. Compares
How Intellia Therapeutics, Inc. compares to Healthcare sector averages
Sector benchmarks are approximate industry averages. Actual sector performance may vary.
Is Intellia Therapeutics, Inc. Stock Overvalued? NTLA Valuation Analysis 2026
Based on fundamental analysis, Intellia Therapeutics, Inc. has mixed fundamental signals relative to the Healthcare sector in 2026.
Note: This is a fundamental analysis based on SEC filings. For P/E ratio, price targets, and market-based valuation, consult financial data providers. This is not investment advice.
Intellia Therapeutics, Inc. Balance Sheet: NTLA Debt, Cash & Liquidity
NTLA Revenue & Earnings Growth: 5-Year Financial Trend
5-Year Trend Summary: Intellia Therapeutics, Inc.'s revenue has grown significantly by 17% over the 5-year period, indicating strong business expansion. The most recent EPS of $-5.42 indicates the company is currently unprofitable.
NTLA Revenue Growth, EPS Growth & YoY Performance
NTLA Quarterly Earnings & Performance
| Quarter | Revenue | Net Income | EPS |
|---|---|---|---|
| Q1 2026 | $15.0M | -$96.2M | $-0.81 |
| Q3 2025 | $9.1M | -$101.3M | $-0.92 |
| Q2 2025 | $7.0M | -$101.3M | $-0.98 |
| Q1 2025 | $16.6M | -$107.4M | $-1.10 |
| Q3 2024 | $9.1M | -$103.1M | $-1.34 |
| Q2 2024 | $7.0M | -$103.1M | $-1.40 |
| Q1 2024 | $12.6M | -$103.1M | $-1.12 |
| Q3 2023 | $12.0M | -$100.7M | $-1.38 |
Data sourced from SEC EDGAR 10-Q quarterly filings. Figures may represent quarterly or cumulative values.
Intellia Therapeutics, Inc. Dividends, Buybacks & Capital Allocation
NTLA SEC Filings: Latest 10-K & 10-Q Analysis
Access official SEC EDGAR filings for Intellia Therapeutics, Inc. (CIK: 0001652130)
📋 Recent SEC Filings
❓ Frequently Asked Questions about NTLA
What is the AI rating for NTLA?
Intellia Therapeutics, Inc. (NTLA) has a Combined AI Rating of SELL from Claude (SELL) and ChatGPT (SELL) with 71% combined confidence, based on fundamental analysis of SEC EDGAR filings.
What are NTLA's key strengths?
Claude: Debt-free balance sheet with $620.9M stockholders' equity eliminates solvency risk. Excellent liquidity position with 6.10x current ratio enabling sustained R&D spending. ChatGPT: Strong liquidity with 5.08x current ratio. No long-term debt and sizable equity base.
What are the risks of investing in NTLA?
Claude: Unsustainable cash burn of $117.3M annually against $134.7M cash reserves yields ~1.2 year runway. Operating losses of $100.5M represent -668% margin on $15M revenue, demonstrating non-viable unit economics. ChatGPT: Sustained large operating losses and >600% negative margins. Severe negative operating cash flow and FCF implying short runway.
What is NTLA's revenue and growth?
Intellia Therapeutics, Inc. reported revenue of $15.0M.
Does NTLA pay dividends?
Intellia Therapeutics, Inc. does not currently pay dividends.
Where can I find NTLA SEC filings?
Official SEC filings for Intellia Therapeutics, Inc. (CIK: 0001652130) including 10-K, 10-Q, and 8-K reports are available on SEC EDGAR.
What is NTLA's EPS?
Intellia Therapeutics, Inc. has a diluted EPS of $-0.81.
How is the AI analysis conducted?
Two independent AI systems — Claude (Anthropic) and ChatGPT (OpenAI) — analyze SEC EDGAR filings including 10-K annual reports and 10-Q quarterly reports. Each AI evaluates financial health, profitability ratios, balance sheet strength, and growth metrics. The combined rating reflects both perspectives for balanced insights.
Is NTLA a good stock to buy right now?
Based on our AI fundamental analysis in May 2026, Intellia Therapeutics, Inc. has a SELL rating with 71% confidence. Review the strengths and risks sections above before making a decision. This is not investment advice.
Is NTLA stock overvalued or undervalued?
Valuation metrics for NTLA: ROE of -15.5% (sector avg: 15%), net margin of -639.5% (sector avg: 12%). Compare these metrics with sector averages to assess valuation.
Should I buy NTLA stock in 2026?
Our dual AI analysis gives Intellia Therapeutics, Inc. a combined SELL rating for 2026. Revenue is data pending, with profitability at or below sector average. Always conduct your own research.
What is NTLA's free cash flow?
Intellia Therapeutics, Inc.'s operating cash flow is $-117.3M, with capital expenditures of $79.0K. FCF margin is -780.3%.
How does NTLA compare to other Healthcare stocks?
Vs Healthcare sector averages: Net margin -639.5% (avg: 12%), ROE -15.5% (avg: 15%), current ratio 6.10 (avg: 2).